12 active shortage notices across 4 countries · 2 anticipated.
Last updated 1 Nov 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| United States | critical | 8 | 1 Jan 2012 | — | FDA |
| Canada | medium | 2 | 15 Apr 2016 | — | HC |
| Belgium |
| medium |
| 1 |
| 10 Jun 2026 |
| 22 Jul 2026 |
| FAMHP |
| Taiwan | medium | 1 | 13 Aug 2025 | 30 Sept 2025 | TFDA |
Yes. As of the latest regulator updates, Atropine Sulfate has 12 active shortage notices across 4 countries (United States, Canada, Belgium, Taiwan). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Atropine Sulfate shortages to manufacturing problems, product discontinuation, causes not stated by the regulator. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 30 Sept 2025 to 22 Jul 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Atropine (Sulfate) · Atropine Sulfate Ophthalmic Solution · Atropine Sulfate Injection · Atropine Injection Bp 0.4Mg/Ml (2015 · Atropine Sulfate Injection Solution · Atropine
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.